FDA advisory panel backs Pfizer’s RSV vaccine, but expresses some safety concerns
A committee of vaccine experts voted to recommend the Food and Drug Administration approve Pfizer’s maternal RSV vaccine on Thursday, though the panel expressed some safety concerns.
The Vaccines and Related Biological Products Advisory Committee voted 14-0 that Pfizer’s data showed the vaccine was effective in preventing severe disease in infants born to people who were vaccinated during pregnancy. But on a second question — whether the available data support the safety of immunization with this vaccine — the committee voted 10 to 4.
